Pharmaceutical Opinion Leaders Come at a Premium
Pharmaceutical thought leaders are in high demand because of their expertise, experience and know-how. According to a new study conducted by Cutting Edge Information (http://www.PharmaOpinionLeaders.com), the most influential and, therefore, premium thought leaders are garnering $25,000 to $50,000 annually in supplemental income for consulting.
Key opinion leaders (KOL) are called upon to deliver keynote speeches to organizations as well as at conferences. These KOLs are garnering high prices because pharmaceutical companies are looking to gain industry insight from experts with experience and objective views.
Globally influential physicians, considered top-tier in the industry, are cashing in due to their high-demand and low supply. Tier-two physicians are also able to deliver their wealth of knowledge and command $10,000 to $25,000. One reason for the low supply of these KOLs is that there are so many pharmaceutical organizations vying for a limited number of top-level, influential KOLs.
"Thought leader management groups have to work with commercial teams to budget their thought leader activities to include promotional speeches and advisory panel leadership," said Elio Evangelista, Research Team Leader at Cutting Edge Information. "Companies need to be strategic in the way they approach their top-tier thought leaders and to attract KOLs to build relationships with their organizations."
"Pharmaceutical Opinion Leader Management," available at http://www.PharmaOpinionLeaders.com, explores the gamut of the pharmaceutical KOL process. This report outlines the ways that many organizations are forming partnerships with KOLs in order to best serve their internal needs, and provide them with an advantage in a very competitive industry. Some specific areas of concern that are detailed include regulation, recruitment, compliance and efficacy.
Source : www.marketwire.com
Key opinion leaders (KOL) are called upon to deliver keynote speeches to organizations as well as at conferences. These KOLs are garnering high prices because pharmaceutical companies are looking to gain industry insight from experts with experience and objective views.
Globally influential physicians, considered top-tier in the industry, are cashing in due to their high-demand and low supply. Tier-two physicians are also able to deliver their wealth of knowledge and command $10,000 to $25,000. One reason for the low supply of these KOLs is that there are so many pharmaceutical organizations vying for a limited number of top-level, influential KOLs.
"Thought leader management groups have to work with commercial teams to budget their thought leader activities to include promotional speeches and advisory panel leadership," said Elio Evangelista, Research Team Leader at Cutting Edge Information. "Companies need to be strategic in the way they approach their top-tier thought leaders and to attract KOLs to build relationships with their organizations."
"Pharmaceutical Opinion Leader Management," available at http://www.PharmaOpinionLeaders.com, explores the gamut of the pharmaceutical KOL process. This report outlines the ways that many organizations are forming partnerships with KOLs in order to best serve their internal needs, and provide them with an advantage in a very competitive industry. Some specific areas of concern that are detailed include regulation, recruitment, compliance and efficacy.
Source : www.marketwire.com
Posts
Post a Comment